Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Clinical trial NCT02595424 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02595424
Sponsor: ECOG-ACRIN Cancer Research Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Neuroendocrine Carcinoma Intestinal Neuroendocrine Carcinoma Pancreatic Neuroendocrine Carcinoma

Start date: 2015-11-06
Primary completion: 2025-04-23
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.